Sugar-Coded Signals: Glycan-Based Biomarkers in Rheumatoid Arthritis.

IF 6.3 2区生物学 Q1 BIOCHEMICAL RESEARCH METHODS

Molecular & Cellular Proteomics Pub Date : 2026-09-01 Epub Date: 2026-08-04 DOI:10.1016/j.mcpro.2026.101633

Michal Hires, Stefania Hroncekova, Viera Dujnič, Veronika Solovicova, Veronika Pinkova Gajdosova, Eduard Jane, Lenka Lorencova, Tomas Bertok, Alica Vikartovska, Anna Datkova, Peter Kasak, Radek Kucera, Jan Tkac

引用次数: 0

Abstract

This review paper summarizes the pathophysiology of rheumatoid arthritis (RA), its incidence and etiology, and conventional RA protein-based biomarkers. A brief overview of novel protein-based biomarkers and biomarkers with potential to be used in the diagnostics of seronegative RA is also provided. The core of the review resides in the comprehensive characterization of the glycosylation of immunoglobulins and their utility as novel biomarkers for the diagnostics of RA and seropositive RA. Two main approaches to the analysis of glycans present on immunoglobulins and other proteins are provided, including instrument-based and lectin-based approaches showing their clinical performance as RA biomarkers.

查看原文本刊更多论文

糖编码信号：类风湿性关节炎中基于聚糖的生物标志物。

本文综述了类风湿性关节炎（RA）的病理生理学、发病率和病因，以及常规的基于RA蛋白的生物标志物。简要概述了新的基于蛋白质的生物标志物和可能用于诊断血清阴性RA的生物标志物。该综述的核心在于免疫球蛋白糖基化的综合表征及其作为诊断RA和血清阳性RA的新型生物标志物的实用性。提供了两种主要的方法来分析存在于免疫球蛋白和其他蛋白质上的聚糖，包括基于仪器和基于凝集素的方法，显示它们作为RA生物标志物的临床性能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular & Cellular Proteomics 生物-生化研究方法

CiteScore

11.50

自引率

4.30%

发文量

131

审稿时长

84 days

期刊介绍： The mission of MCP is to foster the development and applications of proteomics in both basic and translational research. MCP will publish manuscripts that report significant new biological or clinical discoveries underpinned by proteomic observations across all kingdoms of life. Manuscripts must define the biological roles played by the proteins investigated or their mechanisms of action. The journal also emphasizes articles that describe innovative new computational methods and technological advancements that will enable future discoveries. Manuscripts describing such approaches do not have to include a solution to a biological problem, but must demonstrate that the technology works as described, is reproducible and is appropriate to uncover yet unknown protein/proteome function or properties using relevant model systems or publicly available data. Scope: -Fundamental studies in biology, including integrative "omics" studies, that provide mechanistic insights -Novel experimental and computational technologies -Proteogenomic data integration and analysis that enable greater understanding of physiology and disease processes -Pathway and network analyses of signaling that focus on the roles of post-translational modifications -Studies of proteome dynamics and quality controls, and their roles in disease -Studies of evolutionary processes effecting proteome dynamics, quality and regulation -Chemical proteomics, including mechanisms of drug action -Proteomics of the immune system and antigen presentation/recognition -Microbiome proteomics, host-microbe and host-pathogen interactions, and their roles in health and disease -Clinical and translational studies of human diseases -Metabolomics to understand functional connections between genes, proteins and phenotypes